Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
D
Davanidavari, Dorna
Chapman University
(
W1030-02-09
)
Design and Evaluation of a Cyclic Peptide-Epirubicin Conjugate to Enhance Anticancer Activity and Reduce Cardiac Toxicity
Dorna Davanidavari
Favorite
Davies, John
Genentech, Inc.
(
T1130-02-07
)
Anti-CCR8 Mediated Depletion of Tumor-Infiltrating Regulatory T Cells: Preclinical PK/PD and Translational Strategy in Support of Clinical Development for Solid Tumor Indications
John Davies
Favorite
Davis, Don
Janssen Research & Development, LLC
(
T1130-02-09
)
Evaluation of Sample Preparation Techniques for Protein Quantification
Don Davis
Favorite
DeGroot, Anne
EpiVax, Inc.
(
T1130-02-11
)
Rapid and Predictive Immunogenicity Risk Assessments Using In Silico Methods
Anne DeGroot
Favorite
(
W1130-02-09
)
Immunogenicity Risk Assessment of Salmon Calcitonin Peptide Impurities Using In Silico and In Vitro Methods
Anne DeGroot
Favorite
(
W1230-02-11
)
Comprehensive Assessment of Immunogenicity Risk of Host Cell Proteins in Biologics and Vaccines Using In Silico and In Vitro Methods
Anne DeGroot
Favorite
de Leeuw, Erik
LabCorp
(
W1230-01-05
)
Development of a Marburg Self-amplifying mRNA-Lipid Nanoparticle Vaccine: Differential Effects When Co-formulated with Toll Receptor Agonists
Erik de Leeuw
Favorite
DeGroot, Anne
EpiVax, Inc.
(
W1530-02-10
)
An “I” (Immunogenicity Risk Assessment) for an Eye (Ophthalmology Biologics)
Anne DeGroot
Favorite
Del Rosario, Geoffrey
Genentech, Inc.
(
T1030-02-09
)
Evaluating the Effects of Differently Charged Linker-Drugs on Pharmacokinetics and Tissue Distribution of Antibody Drug Conjugates
Geoffrey Del Rosario
Favorite
DelCarpini, Jason
Moderna Therapeutics
(
T1530-02-06
)
Development of an Electrochemiluminescent Assay for the Detection of Anti-PEG IgE Antibodies in Human Serum
Jason DelCarpini
Favorite
Deng, Bijia
Wave Life Sciences
(
W1230-02-06
)
Strategies for the Development and Characterization of Sensitive Anti-oligonucleotide Antibodies for Application in Anti-drug Antibody Assays
Bijia Deng
Favorite
DeSilva, Binodh
Ultragenyx Pharmaceuticals
(
W1430-02-10
)
Analysis of Anti-Drug Antibodies (ADA) in Multiple Animal Species from mRNA LNP Therapeutics Supporting Rare Diseases Demonstrated Low Immunogenicity of PEG-2000 by ECLA and ELISA Methodology
Binodh DeSilva
Favorite
Dhungana, Suraj
Waters Corporation
(
W1330-02-10
)
Next-Generation Biocompatible HPLC System for Enhanced Analysis of Biotherapeutics
Suraj Dhungana
Favorite
Diaz-Botia, Camilo
NeuroOne
(
W1430-01-04
)
Innovative Device for Concomitant Therapeutic Compound Delivery into the Brain and Neural Recordings - Feasibility Bench and In Vivo Studies
Camilo Diaz-Botia
Favorite
Ding, Ling
University of Nebraska Medical Center
(
T1230-01-05
)
Development of Inhalable Polymeric Nanoemulsions for Delivery of Gene Silencing Therapeutics in Lung Tumors
Ling Ding
Favorite
Dockrey, Summer
Genentech, Inc.
(
T1030-02-09
)
Evaluating the Effects of Differently Charged Linker-Drugs on Pharmacokinetics and Tissue Distribution of Antibody Drug Conjugates
Summer Dockrey
Favorite
Dragovich, Peter
Genentech, Inc.
(
T1030-02-09
)
Evaluating the Effects of Differently Charged Linker-Drugs on Pharmacokinetics and Tissue Distribution of Antibody Drug Conjugates
Peter Dragovich
Favorite
Druschitz, Amy
Croda, Inc.
(
T1330-01-05
)
Optimizing Lipid Nanoparticles (LNPs) Processing for siRNA Delivery by Microfluidics System
Amy Druschitz
Favorite
Dubey, Sheri
Merck Sharp & Dohme Corp.
(
W1330-02-11
)
One Drop of Blood, Multiple Sets of Data --- Establishing A Common Protocol for Serotype Specific IGG Concentration Testing Using Mitra® VAMS Dry Blood Samples to Support Vaccine Clinical Studies
Sheri Dubey
Favorite
Duong-Ly, Krisna
Merck & Co., Inc.
(
T1530-02-09
)
False Positive or Not? – Assessing Potential Interference of Soluble Target to ADA Detection for a Clinical Stage Program
Krisna Duong-Ly
Favorite
Du, Xiangsha
Waters Corporation
(
W1330-02-10
)
Next-Generation Biocompatible HPLC System for Enhanced Analysis of Biotherapeutics
Xiangsha Du
Favorite
